CRBU Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Caribou Biosciences Inc (CRBU) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive developments in the biotech pipeline and hedge funds are increasing their positions, the company's financial performance is weak, and technical indicators do not suggest a strong entry point. Additionally, there are no significant recent news or catalysts to drive immediate growth.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 54.216, and moving averages are converging, showing no clear trend. The stock is trading near the pivot level of 1.886, with resistance at 1.98 and support at 1.793.
Hedge funds are significantly increasing their positions, with a 1731.04% increase in buying over the last quarter. Analysts have raised price targets recently, and the company is developing promising CAR-T therapies, including vispa-cel, which is preparing for a Phase 3 study.
The company's financials show a significant net income loss (-25.36% YoY) and declining EPS (-28.21% YoY). No recent news or significant events have been reported to drive immediate growth. Insider trading trends are neutral, and there is no recent congress trading data.
In Q4 2025, revenue increased by 89.74% YoY to $3.94M, but net income dropped to -$26.49M (-25.36% YoY), and EPS declined to -0.28 (-28.21% YoY). Gross margin remains strong at 100%, but profitability is a concern.
Analysts are generally positive, with recent price target increases to $13 from Evercore ISI and Clear Street. However, funding challenges for pivotal studies and a lowered price target from BofA to $6 highlight mixed sentiments.
